IL92012A - A process for activating proteins produced by genetic technology expressed in prokaryotes - Google Patents

A process for activating proteins produced by genetic technology expressed in prokaryotes

Info

Publication number
IL92012A
IL92012A IL9201289A IL9201289A IL92012A IL 92012 A IL92012 A IL 92012A IL 9201289 A IL9201289 A IL 9201289A IL 9201289 A IL9201289 A IL 9201289A IL 92012 A IL92012 A IL 92012A
Authority
IL
Israel
Prior art keywords
litre
process according
mole
concentration
mmole
Prior art date
Application number
IL9201289A
Other languages
English (en)
Hebrew (he)
Other versions
IL92012A0 (en
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of IL92012A0 publication Critical patent/IL92012A0/xx
Publication of IL92012A publication Critical patent/IL92012A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
IL9201289A 1988-10-17 1989-10-17 A process for activating proteins produced by genetic technology expressed in prokaryotes IL92012A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3835350A DE3835350A1 (de) 1988-10-17 1988-10-17 Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern

Publications (2)

Publication Number Publication Date
IL92012A0 IL92012A0 (en) 1990-07-12
IL92012A true IL92012A (en) 1994-12-29

Family

ID=6365312

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9201289A IL92012A (en) 1988-10-17 1989-10-17 A process for activating proteins produced by genetic technology expressed in prokaryotes

Country Status (12)

Country Link
US (1) US5077392A (ja)
EP (1) EP0364926B1 (ja)
JP (1) JPH0793879B2 (ja)
KR (1) KR920010873B1 (ja)
AT (1) ATE101650T1 (ja)
AU (1) AU609645B2 (ja)
CA (1) CA2000604C (ja)
DD (1) DD285613A5 (ja)
DE (2) DE3835350A1 (ja)
DK (1) DK175439B1 (ja)
ES (1) ES2061876T3 (ja)
IL (1) IL92012A (ja)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
US5676947A (en) * 1989-02-07 1997-10-14 Boehringer Manneheim Gmbh Method for treating thromboembolic conditions using thrombolytically active proteins
DE4037196A1 (de) * 1990-11-22 1992-05-27 Boehringer Mannheim Gmbh Verfahren zur reaktivierung von denaturiertem protein
DE4105480A1 (de) * 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
CA2109820A1 (en) * 1992-03-24 1993-09-30 George N. Cox Refolding and purification of insulin-like growth factor i
JP3695467B2 (ja) * 1993-02-04 2005-09-14 ボレアン ファーマ エー／エス タンパクを再生するための改良された方法
DE69636739T2 (de) * 1995-12-21 2007-10-18 Ajinomoto Co., Inc. Verfahren zur rückfaltung von menschlichem activin a
AU2660397A (en) * 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US6083715A (en) * 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
ATE395933T1 (de) 1997-08-15 2008-06-15 Chugai Pharmaceutical Co Ltd Präventiva oder arzneien enthaltend neutralisierende anti-il6-rezeptor antikörper zur reduktion urinären proteins bei systemischen lupus erythematosus
AU4975699A (en) * 1998-07-09 2000-02-01 University Technology Corporation High pressure refolding of protein aggregates and inclusion bodies
EP1077263A1 (de) * 1999-07-29 2001-02-21 F.Hoffmann-La Roche Ag Verfahren zur Herstellung von natürlich gefalteten und sekretierten Proteinen durch Co-Sekretion von Chaperonen
WO2001019970A2 (en) * 1999-09-15 2001-03-22 Eli Lilly And Company Chymotrypsin-free trypsin
US6808902B1 (en) * 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2002062827A2 (en) * 2000-10-31 2002-08-15 The Regents Of The University Of Colorado, A Body Corporate Improved protein disaggregation and refolding using high pressure
DE10105912A1 (de) * 2001-02-09 2002-08-14 Roche Diagnostics Gmbh Rekombinante Proteinase K
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
DE602007012412D1 (de) * 2005-12-22 2011-03-24 Genentech Inc Rekombinante produktion heparinbindender proteine
DE102006009437A1 (de) 2006-03-01 2007-09-13 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
WO2008008975A2 (en) 2006-07-14 2008-01-17 Genentech, Inc. Refolding of recombinant proteins
EP2059523A2 (en) * 2006-09-15 2009-05-20 Barofold, Inc. High pressure treatment of proteins for reduced immunogenicity
NZ601759A (en) 2010-03-17 2013-07-26 Biogenerix Gmbh Method for obtaining biologically active recombinant human g-csf
HUP1200171A1 (hu) 2012-03-19 2013-09-30 Richter Gedeon Nyrt Módszerek polipeptidek elõállítására
WO2013168178A1 (en) * 2012-03-30 2013-11-14 Krishnan Archana Rajesh Process for renaturation of polypeptides
WO2014128726A2 (en) * 2013-02-22 2014-08-28 Biogenomics Limited Process for high efficiency refolding of recombinant proteins
US20160039868A1 (en) * 2013-03-22 2016-02-11 Biogenomics Limited Process for isolation and stabilisation of key intermediates for high efficiency refolding of recombinant proteins
US10457716B2 (en) 2014-08-06 2019-10-29 University Of Notre Dame Du Lac Protein folding and methods of using same
CN110643595A (zh) * 2019-10-21 2020-01-03 黑龙江精益检测有限公司 一种对化学修饰后磁性固定化pla1再活化的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR79124B (ja) * 1982-12-22 1984-10-02 Genentech Inc
US4620948A (en) * 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4634586A (en) * 1984-05-21 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Reagent and method for radioimaging leukocytes
ES8800957A1 (es) * 1985-02-22 1987-12-01 Monsanto Co Un metodo para la solubilizacion y renaturalizacion de proteina somatotropina
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
DE3537708A1 (de) * 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
US4766205A (en) * 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
FR2594845B1 (fr) * 1986-02-21 1989-12-01 Genetica Preparation par voie microbiologique de l'activateur tissulaire humain du plasminogene (t-pa) et conversion de l'enzyme ainsi obtenue en sa forme active
DE3611817A1 (de) * 1986-04-08 1987-10-15 Boehringer Mannheim Gmbh Verfahren zur renaturierung von proteinen

Also Published As

Publication number Publication date
IL92012A0 (en) 1990-07-12
KR920010873B1 (ko) 1992-12-19
AU4293189A (en) 1990-04-26
DD285613A5 (de) 1990-12-19
ES2061876T3 (es) 1994-12-16
JPH02227090A (ja) 1990-09-10
EP0364926B1 (de) 1994-02-16
DK175439B1 (da) 2004-10-18
EP0364926A2 (de) 1990-04-25
CA2000604C (en) 1999-07-06
DE3835350A1 (de) 1990-04-19
US5077392A (en) 1991-12-31
DK515989D0 (da) 1989-10-17
KR900006515A (ko) 1990-05-08
AU609645B2 (en) 1991-05-02
CA2000604A1 (en) 1990-04-17
EP0364926A3 (de) 1991-05-02
DK515989A (da) 1990-04-18
DE58906984D1 (de) 1994-03-24
ATE101650T1 (de) 1994-03-15
JPH0793879B2 (ja) 1995-10-11

Similar Documents

Publication Publication Date Title
IL92012A (en) A process for activating proteins produced by genetic technology expressed in prokaryotes
AU607083B2 (en) Process for the activation of genetically engineered, heterologous, disulphide bridge-containing eukaryotic proteins after expression in prokaryotes
Buchner et al. Renaturation, purification and characterization of recombinant Fab-fragments produced in Escherichia coli
US5453363A (en) Process for the activation of t-PA or Ing after genetic expression in prokaryotes
Rietsch et al. Reduction of the periplasmic disulfide bond isomerase, DsbC, occurs by passage of electrons from cytoplasmic thioredoxin
Clark et al. [15] Inhibition of aggregation side reactions during in vitro protein folding
US8633300B2 (en) Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
Carlson et al. Antibody assisted protein refolding
NO309153B1 (no) Fremgangsmåte for ökning ved sekresjon av disulfidbrodannede proteiner
US4904602A (en) Thioredoxin shufflease and use thereof
CA2157767A1 (en) Genetically engineered enzymes and their conjugates for diagnostic assays
DECKERS‐HEBESTREIT et al. Accessibility of F0 subunits from Escherichia coli ATP synthase: A study with subunit specific antisera
Teale et al. Antibody as immunological probe for studying refolding of bovine serum albumin. Refolding within each domain.
Venkatesh et al. The flavin-containing monooxygenase of mouse kidney: A comparison with the liver enzyme
EP0208539A2 (en) Folding disulfide-cross-linkable proteins
Björnberg et al. Characterization of homogeneous recombinant glutaredoxin from Escherichia coli: purification from an inducible λPL expression system and properties of a novel elongated form
Rydén et al. Covalent chromatography as a means of isolating thiol peptides from large proteins: Application to human ceruloplasmin
Orlando et al. A monoclonal antibody directed against the catalytic site of Bacillus anthracis adenylyl cyclase identifies a novel mammalian brain catalytic subunit
Ueda et al. Effect of chemical modifications of tryptophan residues on the folding of reduced hen egg-white lysozyme
US5310880A (en) Purification of Mullerian inhibiting substance
Jefferis et al. Studies of human IgD myeloma proteins: Proteolytic digestion patterns
Sandberg et al. Escherichia coli glutaredoxin: cloning and overexpression, thermodynamic stability of the oxidized and reduced forms, and report of an N-terminal extended species
Baumann et al. Dihydrofolate reductase from bovine liver: enzymatic and structural properties
Moutin et al. Autonomous folding of the recombinant large cytoplasmic loop of sarcoplasmic reticulum Ca2+‐ATPase probed by affinity labeling and trypsin digestion
US6841658B2 (en) Purification of human Troponin I

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired